Feb 2013 – Redx Oncology continues to experience dramatic growth.

A cancer drug research centre based in Liverpool is looking to fill more than 60 high-value positions having already recruited 60 people since launching in 2012.
Redx Oncology, a private-sector centre for pre-clinical research and novel anti-cancer drug development, launched in April last year and has already created 67 jobs, which span the spectrum from university leavers to senior scientists and project managers.
Positions currently available at Redx Oncology range from junior technicians, to scientists with ten years' experience in industry including senior scientists, senior pharmacologists, and in vitro biology specialists. The company is also offering a range of industrial placements and administrative support roles.

Dr Derek Lindsay, Managing Director at Redx Oncology, said the company had been pleasantly surprised by the level of interest the job vacancies were attracting from talented applicants.
Dr Lindsay said: Redx Oncology is continuing to recruit first-class scientists and professionals from all over the world – boosting Liverpool's knowledge economy and contributing to the growth of the city and the region, and we are delighted to be building on the city's established reputation in cancer care.
The immensely positive response we have had is partly a consequence of the difficult state the pharma industry is in at the moment but it also shows that people are interested in working in the North West and that the region is rapidly developing as a science sector.
The UK pharmaceutical industry has shed over 4,000 science posts in the last two years as major players in the market have closed or consolidated in-house research facilities, but Redx Oncology is bucking the trend as it continues to recruit high-calibre applicants.
Redx Oncology is the first subsidiary of Redx Pharma, an early stage drug development company based in Liverpool, and was awarded a £5.9m grant from the Government's Regional Growth Fund (RGF) in 2011 to support its development. The company plans to create up to 250 bioscience jobs in the city by 2016.

It's anticipated that a significant number of the new jobs being created by the company will be filled by people relocating to Liverpool and applications have been received from scientists and chemists from all over the UK, Europe and the US keen to take up positions at the centre.
Built around Redx Pharma's extensive pipeline of 40 research drug candidate programs in a wide variety of cancer types, the project aims to deliver a pipeline of experimental drugs, for progression into human clinical trials within five years.

Jan 2013 - Redx Oncology staff did deep to raise funds for Liverpool Cancer Research UK Centre.

Staff at a Liverpool cancer drug research centre have donated more than £1,000 to a local charity, after raising the money through their Christmas raffle.

Members of the team at Redx Oncology handed over a cheque for £1,020 to the Liverpool Cancer Research UK Centre at a special event on Friday, January 11th.

Redx Oncology is the first subsidiary of Redx Pharma, an early stage drug development company based in Liverpool. Redx Oncology, is a private-sector centre for pre-clinical research and novel anti-cancer drug development, which launched in April last year.

Dr Derek Lindsay, Managing Director at Redx Oncology, said: We're delighted to be supporting such a worthwhile cause – the Liverpool Cancer Research UK Centre does world-class work which has a significant impact in tackling cancer.

The Redx team has done an amazing job to raise such a significant amount and we will no doubt continue to do all we can to support local charities.
The Liverpool Cancer Research UK Centre brings together scientists, doctors and nurses to boost key areas of research that will produce the greatest benefits for cancer patients in Liverpool, Merseyside and Cheshire. The Centre also focuses on tackling cancer in low incomecommunities in the region, where more people die from the disease.

Professor John Neoptolemos, Head of Surgery and Oncology at the University of Liverpool and an international expert in the treatment of pancreatic cancer who works with the Liverpool Cancer Research UK Centre, accepted the cheque from Dr Lindsay on behalf of the charity.
Professor Neoptolemos said: The Liverpool CRUK Centre is incredibly grateful to be the recipient of Redx Pharma's Christmas fundraising donation. The level of funding needed to produce world class practice-changing research is enormous; therefore, donations like this one are vital.
Improving cancer prevention, diagnosis and treatment, underpinned by world class research and access to the latest therapies is the responsibility of many different organisations. Both the City of Liverpool and the Merseyside and Cheshire Region have the highest cancer mortality of any region in the UK and one of the worst in Europe.

This underlines the importance of the Liverpool Cancer Research UK Centre to bring local partners together in a common goal of reducing cancer mortality. The Liverpool CRUK Centre works closely with Redx Pharma to explore how links and relationships can be developed with its medicinal chemistry centre in Liverpool focusing in oncology.

The Liverpool Cancer Research UK Centre is a partnership between Cancer Research UK, the Royal Liverpool and Broadgreen University Hospitals NHS trust, Clatterbridge Centre of Oncology NHS Foundation Trust, the University of Liverpool, Liverpool City Council and the Merseyside and Cheshire Cancer Network.

Nov 2012 – Redx Pharma shortlisted in the Young Company of the Year category

The awards ceremony, hosted by former Olympian and BBC presenter Steve Cram, honoured UK businesses across ten categories, ranging from Digital Champion to Entrepreneur of the Year.
Redx Pharma was shortlisted in the Young Company of the Year category.

Mark Stokes, Managing Director of Mid Markets, Lloyds Bank Wholesale Banking & Markets, said: It's encouraging to see so much innovation, energy and promise from all corners of the UK and across so many sectors. It's time to champion British enterprise and ensure these businesses reach their full potential in both national and international markets.

Dr Neil Bentley, CBI Deputy-Director General, said: The UK's small and medium-sized firms have some of the greatest potential to grow and increase jobs, so creating the right conditions for them to do business in is critical to the health of our economy.

The CBI is delighted to celebrate the achievements of these firms by supporting the Growing Business Awards.

Matthew Rock, Co-Founder of Real Business, added: This year's candidates are delivering 'economic replenishment'; a breed of new entrepreneurs are breaking into established industries and disrupting the long-standing market leaders. No business can rest on its laurels as they can be assured that a hungry, innovative and determined entrepreneur will soon be snapping at their heels.
The awards are supported by Cass Business School, Business Voice, Professional Engineering, Land Rover, Lloyds Private Banking, Spring Law, Cavendish, Visa, Your Business Your Future, Bdaily Business Network and the Financial Mail.

October - 2012 – UK Business Secretary, Vince Cable visits Redx Pharma; see the video here

October 2012 – Redx Pharma awarded £4.7M grant to build new Anti-Infectives subsidiary.

October 2012 – Redx Pharma nominated for Young Company of the Year at the Growing Business Awards.

October 2012 – Redx Pharma named North Wests most innovative at the annual Institute of Directors Awards